Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis’ business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer and infectious diseases.
Coeptis Therapeutics Holdings, Inc.
Disclaimer: All stock information on InvestorNews.com is currently being fed from multiple sources and is updated automatically every 10-minutes. The information on this site is for information purposes only and InvestorIntel Corp. is neither responsible nor liable for the accuracy of this data.
InvestorNews Features on Coeptis Therapeutics Holdings, Inc.
-
Coeptis Therapeutics’ Dave Mehalick on Making Cell Therapy Universally Accessible
April 30, 2024 — In a recent interview with InvestorNews, Dave Mehalick, Chairman, President, and CEO of Coeptis…
-
Dave Mehalick from Coeptis Therapeutics to Host InvestorTalk (04.25.2024)
InvestorNews is pleased to announce an upcoming InvestorTalk scheduled for Thursday, April 25th at 9 AM EST, featuring…
-
Coeptis Therapeutics’ Dave Mehalick on the disruptive potential of SNAP-CAR technology for autoimmune diseases
In an insightful interview with Tracy Weslosky, Dave Mehalick, Chairman, President, and CEO of Coeptis Therapeutics Holdings, Inc.…
-
Dr. Colleen Delaney from Coeptis Therapeutics on the development of next-generation cell therapy technologies for cancer and infectious diseases
In a recent Investor.Coffee interview with host Jack Lifton, Dr. Colleen Delaney, Chief Scientific and Medical Officer at…
-
Coeptis CEO Dave Mehalick on NASDAQ listing and entering the Cancer Treatment Race
Innovative cell therapy platforms have the potential to disrupt conventional cancer treatment In an InvestorCoffee interview with host…